Contract manufacturing market for live biotherapeutics and microbiome products growing at a CAGR of 46%, {Roots Analysis}

 Manufacturing live biotherapeutic product is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030.”

 

The report features an extensive study of the current landscape and future opportunities related to contract services for microbiome therapeutics. The study features an in-depth analysis, highlighting the capabilities of a diverse set of contract service providers, including CMOs and CDMOs. Amongst other elements, the report includes:

§  A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics.

§  A list of companies with in-house manufacturing facilities for microbiome therapeutics.

§  Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific.

§  An assessment of microbiome contract manufacturing capability in different regions.

§  A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers.

§  A detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players.

§  An estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders.

§  An informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.

§  A qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

§  A review of the varied microbiome-focused initiatives of big pharma players.

 

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):

§  Type of Product Manufactured

§  Active Pharmaceutical Ingredients (APIs)

§  Finish Drug Formulations (FDFs)

 

§  Type of Type of Formulation

§  Solid Formulations

§  Oral Liquids

§  Injectables

§  Others

 

§  Scale of Operation

§  Clinical

§  Commercial

 

§  Company Size

§  Small-sized

§  Mid-sized

§  Large

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific and Rest of the World

 

Key companies covered in the report

§  Biose®

§  BJP Laboratories

§  Capsugel (acquired by Lonza)

§  Cerbios-Pharma

§  Cobra Biologics (acquired Cognate Bioservices)

§  Inpac Probiotics

§   Paragon Bioservices (a unit of Catalent Biologics)

§  UAS Labs

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

 

Other Recent Offerings

1.     HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030

2.     Antibody Contract Manufacturing Market, 2020 – 2030

3.     The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more